

23-FEB-2019 6:11
OPEN STUDIES IRB REPORT

Disease Site	Study	Study Name	Open Date	Number of Active Institutions	Number of Current IRBs
BREAST	S1207	Brst,Adj,Endocrine+/-Everolimus	03-SEP-13	440	205
	S1416	Brst, TNBC/BRCA, Cis+/- ABT-888	07-JUL-16	292	150
	S1418	Breast, Adj, TNBC, MK-3475 (Pembrolizumab)	15-NOV-16	478	210
	S1706	Breast, Inflammatory, RT +/- Olaparib	12-SEP-18	0	56
	A011106	Breast, Neoadj, ALTERNATE study	15-FEB-14	278	114
	A011401	Breast, adj, Stage II/III HER2-, weight loss	29-AUG-16	486	246
	A011502	Brst, Adj, Nodal+&HER2-, Aspirin vs. Placebo	08-DEC-16	0	260
	A221405	Breast, ET interruption, Pregnancy Outcomes	15-OCT-15	0	55
	B51	Breast, Regional Nodal XRT	22-AUG-13	316	170
	B55	Brst, Adj Olaparib for BRCA,TNBC	03-JUL-14	439	185
	E1Z11	Brst,Genetic Predictors of AIMSS	10-MAY-13	17	11
	EA1151	Brst, Tomosynthesis Mammographic Screening	06-JUL-17	0	72
	NRGBR002	Brst, OMBC, II-III, SoC +/- SBRT and/or SA	24-DEC-14	0	141
	NRGBR003	Brst,Adj,TNBC,AC -> WP +/- Carbo	22-JAN-15	337	173
	NRGBR005	Br, Stg II&IIIA, Post NAdj Chemo Br Conserv	13-APR-17	0	78
	CCD	S1415CD	TrACER CSF Standing Order Intervention for FN	01-SEP-16	2
S1703		Met Breast, STM-monitoring v Usual Care	16-JUL-18	0	65
A011104		Preoperative Breast MRI	21-FEB-14	76	17
A191402C		PROS, Testing Decision Aids for Minority Men	14-JUL-17	0	10
ACCL16N1		Guideline Consistent Treatment AYA ALL	18-DEC-17	0	10
EAQ162CD		CCD, Financial Burden, Colon & Rectal Cancer	17-MAY-18	0	67
ERLYTX	S1609	Rare Tumor, Comb Nivo/Ipi	13-JAN-17	318	157
	A071401	Prog Meningiomas,SMO/AKT/NF2 Inhib	06-AUG-15	227	91
	ARST1321	NonRhabdo STS,Pazopanib (PAZNTIS)	16-MAY-14	261	119
	EAY131	MATCH	12-AUG-15	384	207
GI	S1613	mCRC, Adv/Met, TP vs CETIRI	09-OCT-17	0	142
	S1815	Biliary, Met/LocAdv, GC+CPT±Nab-paclitaxel	03-DEC-18	0	44
	A021501	Adeno Panc,Borderline Resect,Chemo vs ChemoRT	01-DEC-16	0	15
	A021502	Colon, Stg III, Chemo +/- Atezol, ATOMIC	12-SEP-17	0	157
	EA2142	GI NEC, Adv G3, EP vs TMZ + CAP	06-NOV-15	170	69
	EA2161	PANC, Adv Rapalog Resistant PNETs, MLN0128	01-FEB-17	0	11
	EA2165	Anal, Stg II-III, Nivolumab after CMT	13-APR-18	0	33
	NRGGI004	Colorectal, Stg IV, dMMR Immuno-Therapy	07-NOV-17	0	117

23-FEB-2019 6:11
OPEN STUDIES IRB REPORT

<u>Disease Site</u>	<u>Study</u>	<u>Study Name</u>	<u>Open Date</u>	<u>Number of Active Institutions</u>	<u>Number of Current IRBs</u>
GU	S1500	pRCC,Adv, Sunitinib vs MET inhib	05-APR-16	211	88
	S1602	Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG	07-FEB-17	182	70
	S1605	Blad, BCG-Unresponsive NMIBC, Atezolizumab	07-FEB-17	195	92
	S1802	Pros, Stg IV, SST +/- Surg/RT to Primary Tum	17-SEP-18	0	80
	A031102	GCT, Recur, Std Chemo(TIP) vs HD Chemo(TI-CE)	01-JUL-15	55	34
	A031501	Bladder, MIBC/Loc Adv, Adjv Pembro vs Obs	21-SEP-17	0	123
	A031701	Bladder, ddGC for MIBC with DDR Tumor Alt	01-AUG-18	0	3
	EA8143	RCC, HR, Surg +/- Nivolumab (PROSPER)	02-FEB-17	0	146
	EA8153	Pros, ADT + Abira +/- Cabazitaxel (CHAARTED2)	08-FEB-18	0	24
	NRGGU002	Pros, RT + ADT After RP +/- Adj Docetaxel	30-DEC-16	0	108
	R0924	Pros, NADT+WPRT vs. NADT+P&SV RT	07-JUL-11	0	122
	LEUK	S1712	CML, chronic phase, TKI +/- Ruxolitinib	20-JUL-18	0
A041501		B-Cell ALL, Frontline Tx +/- Intuzumab Ozo	01-JUN-17	0	52
E1910		BCR-ABL-neg, B ALL, Blinatumomab	23-DEC-13	174	86
E2906		AML, Age 60+, Clo vs Dauno+Cy	24-FEB-11	155	70
NHLBIMDS		LEUK, National MDS Study	05-APR-16	212	81
LUNG	S1400F	Non-Match: MEDI4736 + Tremelimumab	02-OCT-17	0	206
	S1619	Meso,Stg I-III, Nadj chemo/Atezmb->Atezmb+SOC	03-NOV-17	0	24
	S1701	Thymic Adv, Carbo/Pac/Ram vs. Carbo/Pac	09-AUG-18	0	21
	S1900A	LOH and/or BRCA: Rucaparib	28-JAN-19	0	39
	A081105	ALCHEMIST1, EGFR mut, Erlotinib	02-JAN-14	0	253
	A151216	ALCHEMIST0 - screening	06-FEB-14	493	253
	C30610	SCLC, Thoracic RT	21-MAR-08	166	86
	E4512	ALCHEMIST2, ALK mut, Crizotinib	18-AUG-14	380	218
	EA5142	ALCHEMIST3, Non-match, Nivolumab	16-MAY-16	468	250
	LUNGMAP	NSCLC, Adv, Master	28-JAN-19	0	91
	NRGCC003	SCLC, PCI or HA-PCI	07-DEC-15	257	125
LYMPH	S1608	FL, TGR-1202/Lenalidomide/CHOP or Benda +Ob	10-AUG-17	0	106
	A051301	ABC DLBCL, Auto HCT and Ibrutinib/Placebo	15-JUL-16	166	68
	EA4151	Lymph, AHCT +/-Ritux, MRD Neg	29-AUG-17	0	60
MELAN	S1320	Adv, BRAF mut, Inter v Contin	22-JUL-14	233	98
	S1512	Melan, Adv, Desmoplastic, MK-3475 (pembro)	20-OCT-16	89	41
	S1607	MELAN, Adv, T-VEC, MK-3475	02-OCT-17	0	19
	S1616	MELAN, Adv, Ipilimumab ± Nivolumab	17-JUL-17	0	109

23-FEB-2019 6:11
OPEN STUDIES IRB REPORT

<u>Disease Site</u>	<u>Study</u>	<u>Study Name</u>	<u>Open Date</u>	<u>Number of Active Institutions</u>	<u>Number of Current IRBs</u>
	S1801	Melan, Adv, Adj vs Neoadj Pembrolizumab	06-DEC-18	0	52
	EA6134	Adv, BRAF mut, D+T/Ipi+Niv vs Ipi+Niv/D+T	15-DEC-15	364	144
	EA6141	Melan, Avd, Nivolumab+Ipi ± Sargmostim	01-MAR-16	225	94
MMYEL	S1702	AL Amyloidosis, Relapsed, Isatuximab	08-MAR-18	0	70
	E1A11	MM, frontline, BLD vs CLD	22-NOV-13	300	125
OTHER	A091401	Sarc,	18-JUN-15	183	72
	EA3132	HN SCC, Stg III-IV , Adj RT +/- Cisp	29-MAR-16	0	68
	EAF151	Brain, GBM, Bev, Blood Volume	14-APR-17	0	34
	EAQ152	Communication & education in tumor profiling	26-SEP-16	183	78
	G0263	Cerv, Stg I/IIA, adjv RT vs chemoRT	12-APR-10	0	63
	N0577	BRN, Glio, Tem vs Tem+RT vs RT+PVC	22-SEP-09	172	77
	NRGBN001	HN, novel vs. std chemoradiation + chemo	28-AUG-15	0	77
	NRGGY005	OVAR, Cedir vs Olaparib vs C+O vs Std of Care	06-FEB-16	334	144
	NRGGY009	Ovar, PLD/Atexo vs PLD/Atezo/Bev vs PLD/Bev	12-MAY-17	0	127
	NRGHN001	Nasopharyngeal , Individual Tx EBV	21-APR-14	210	75
	R0724	Cervical, Chem+RT +/- Adj. Chemo	15-JAN-14	195	82
	R1216	HN, Adv,Cis vs Dtx vs Dtx+Cetux	18-MAR-13	202	84
PREV	S0820	PACES: ColrecStg0-3 Blind DFMO/Sulindac	01-MAR-13	50	18
	A211102	Breast, Atypia via RPFNA, Metformin v Placebo	01-FEB-15	0	3
SURV	S1501	Surv, Breast Stg IV, Card Tox w/ Carvedilol	15-SEP-17	0	111
	E1Q11	EROS: Reproductive Health in Cancer Survivors	30-SEP-15	0	38
	EA9131	Leuk, Strategy to decrease early APL deaths	16-AUG-17	0	26
SXQOL	A221101	Glioma, Nuvigil/Placebo Fatigue	03-JUN-13	53	15
	A221504	NSCL, Advanced, placebo vs naloxegol	13-OCT-17	0	5
	A221505	Brst, Hypofractionated Post Mast Rad	01-FEB-18	0	91